Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, Brazil.
about
Interventions for American cutaneous and mucocutaneous leishmaniasisDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil.Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.Oral manifestations in the American tegumentary leishmaniasis.An update on pharmacotherapy for leishmaniasisCutaneous and mucocutaneous leishmaniasis.Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.Comparison of the sensitivity of imprint and scraping techniques in the diagnosis of American tegumentary leishmaniasis in a referral centre in Rio de Janeiro, Brazil.Cost-effectiveness of prevention strategies for American tegumentary leishmaniasis in Argentina.Endemic tegumentary leishmaniasis in Brazil: correlation between level of endemicity and number of cases of mucosal diseaseRisk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil.Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate.Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
P2860
Q24241646-4D2A4DCC-0C29-4039-943D-7430AEFE5F57Q30275257-34598357-9A8C-476F-B544-1B7289231A07Q33739398-8FF90451-7134-446C-A853-B6A45E5AB1BAQ34040777-82EB1C04-AE7B-4417-95F7-E187799A28CAQ34489065-63CCA286-A93D-4B97-9B8E-AED07B46D690Q34945204-3F51200A-BF21-4B33-9742-24AE399200C7Q37627325-F7DD8565-11B5-4D90-93B9-5281E0DC3E2BQ38136837-62C6B0B8-8FBD-4855-AA20-434C56436DA5Q38156421-29270A78-BA74-4B1A-870C-431748139B2AQ38423256-751F475F-E4E9-476F-91DE-4949EC5E7069Q39326575-56A68F83-9532-4AEE-9DED-1724C75684DEQ42749352-FDA1C252-3E14-40A4-A62B-41EB94B9A5B3Q43033883-AC09ACB8-1228-4689-9E65-225E89235F58Q46491606-DC30E0AC-05FB-44FB-8FF2-D687695223E7Q47118269-B2585896-39F6-4AF4-85F1-8C010FBD7EC9Q53588405-EE314EED-A5E2-41AF-8C9E-25E68CBD6924
P2860
Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, Brazil.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Mucosal leishmaniasis ("espund ...... me) in Rio de Janeiro, Brazil.
@ast
Mucosal leishmaniasis ("espund ...... me) in Rio de Janeiro, Brazil.
@en
type
label
Mucosal leishmaniasis ("espund ...... me) in Rio de Janeiro, Brazil.
@ast
Mucosal leishmaniasis ("espund ...... me) in Rio de Janeiro, Brazil.
@en
prefLabel
Mucosal leishmaniasis ("espund ...... me) in Rio de Janeiro, Brazil.
@ast
Mucosal leishmaniasis ("espund ...... me) in Rio de Janeiro, Brazil.
@en
P2093
P2860
P1476
Mucosal leishmaniasis ("espund ...... me) in Rio de Janeiro, Brazil.
@en
P2093
Fernandes O
Gonçalves-Costa SC
Grimaldi G Jr
Oliveira-Neto MP
P2860
P304
P356
10.1590/S0036-46652000000600004
P577
2000-11-01T00:00:00Z